Keytruda takes on adcetris in battle against tough hodgkin lymphoma
NCT ID NCT02684292
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) works better than the targeted drug brentuximab vedotin (Adcetris) for people with classical Hodgkin lymphoma that has relapsed or not responded to prior therapy. 304 participants were randomly assigned to receive one of the two drugs for up to 35 three-week cycles. The main goals were to see if pembrolizumab could delay cancer progression and improve overall survival compared to brentuximab vedotin.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) and brentuximab vedotin (Adcetris)
What this could lead to
If pembrolizumab works better than brentuximab vedotin, it could offer a more effective treatment option for people with Hodgkin lymphoma that has come back or not responded to prior therapy.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all patients. Pembrolizumab can cause immune-related side effects, and it may not improve survival as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.